incretin

incretin. Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. They are secreted from the gastrointestinal tract in response to nutrient ingestion and act by augmenting glucose-stimulated insulin secretion from the pancreatic beta cells, an effect known as the incretin effect. The discovery of this enteroendocrine axis fundamentally altered the understanding of glucose homeostasis and has led to major therapeutic advances in the management of type 2 diabetes.

Definition and discovery

The concept of an intestinal factor influencing the pancreas was first suggested by early 20th-century physiologists. In 1902, William Bayliss and Ernest Starling discovered secretin, demonstrating that chemical messengers from the gut could regulate organ function. The specific "incretin effect" was quantified in the 1960s by researchers including Perley and Kipnis, who showed that oral glucose administration provoked a significantly greater insulin response than intravenous glucose, despite similar blood glucose levels. This work, conducted at institutions like the University of Washington, established that factors from the gut, later termed incretins, were responsible for this amplification. The subsequent isolation and characterization of these hormones relied heavily on techniques developed at laboratories such as the Massachusetts General Hospital and the University of Copenhagen.

Types of incretins

The two primary incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), both members of the secretin family of peptides. GLP-1 is primarily secreted by L-cells located in the distal ileum and colon, as well as in the brainstem. GIP is produced by K-cells found in the duodenum and jejunum. Both are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which limits their circulating half-life to just minutes. Other peptides, such as oxyntomodulin and glicentin, are co-secreted with GLP-1 and may contribute to its effects, but GLP-1 and GIP are considered the dominant mediators of the incretin effect in humans.

Physiological role

Upon secretion, incretins exert their primary action by binding to specific G protein-coupled receptors on pancreatic beta cells. This binding activates pathways involving cyclic AMP and protein kinase A, leading to a potent, glucose-dependent enhancement of insulin secretion. GLP-1 also suppresses glucagon secretion from pancreatic alpha cells, slows gastric emptying via actions on the vagus nerve, and promotes satiety through central receptors in the hypothalamus and brainstem. GIP, in addition to its insulinotropic effect, may promote lipid metabolism and has effects on bone biology. The integrated action of these hormones, coordinated with neural signals, ensures efficient nutrient disposal and metabolism following a meal.

Clinical significance

The incretin system is a major therapeutic target in type 2 diabetes, where the incretin effect is often diminished. Two main classes of drugs have been developed: GLP-1 receptor agonists (e.g., exenatide, liraglutide, semaglutide) and DPP-4 inhibitors (e.g., sitagliptin, saxagliptin). GLP-1 receptor agonists, developed by companies like Novo Nordisk and Eli Lilly and Company, resist DPP-4 degradation and provide pharmacological levels of GLP-1 activity, improving glycemic control and often promoting weight loss. DPP-4 inhibitors, pioneered by Merck & Co., prolong the activity of endogenous GLP-1 and GIP. These therapies are endorsed in guidelines from the American Diabetes Association and the European Association for the Study of Diabetes.

Research and future directions

Current research extends beyond glycemic control, exploring the cardiorenal and neuroprotective benefits of GLP-1 receptor agonists, as demonstrated in large outcomes trials like LEADER and SUSTAIN-6. Investigators at the Joslin Diabetes Center and the University of Oxford are studying the potential of these agents in conditions such as heart failure, non-alcoholic steatohepatitis (NASH), and Alzheimer's disease. Future directions include the development of oral GLP-1 agonists, dual and triple agonists targeting receptors for glucagon and glucose-dependent insulinotropic polypeptide, and gene therapy approaches. Organizations like the National Institute of Diabetes and Digestive and Kidney Diseases continue to fund research into the fundamental biology of L-cells and the enteroendocrine system. Category:Hormones Category:Diabetes